Skip to content
Clinical Trials – home
SwedenBack to Sweden

Clinical trials in Höllviken – page 113

1 391 clinical trials in Höllviken, Sweden. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Höllviken at a glance
1 391
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 391 trials in Höllviken

Open in trial search

Study on Luspatercept and Epoetin Alfa for Treating Anemia in Patients with Low to Intermediate Risk Myelodysplastic Syndromes Needing Blood Transfusions

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Epoetin Alfa
  • Sponsor:Celgene Corp.

Endometrial cancer

Not recruiting

Study on GEN1046 and Pembrolizumab for Patients with Advanced Endometrial Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:GEN1046
  • Sponsor:Genmab A/S

Study on Reduced BCG Dwell-Time for Patients with High-Risk Urothelial Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Bcg (Bacillus Calmette-Guérin) Bacteria
  • Sponsor:Aarhus University Hospital

Tourette's disorder

Not recruiting

Study on the Long-Term Safety of Ecopipam Hydrochloride Tablets for Children, Adolescents, and Adults with Tourette's Disorder

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ecopipam Hydrochloride
  • Sponsor:Emalex Biosciences Inc.

Study on Milvexian and Drug Combination for Patients Recovering from a Heart Attack

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Janssen Cilag International

Hodgkin's disease

Not recruiting

Study Comparing MK-4280A (Favezelimab and Pembrolizumab) with Chemotherapy for Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Ewing's sarcoma+1

Not recruiting

Study of Regorafenib with Chemotherapy for Newly Diagnosed Patients with Metastatic Ewing Sarcoma

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:Regorafenib
  • Sponsor:Institut Gustave Roussy

Endometrial cancer

Not recruiting

Study of Pembrolizumab with Chemotherapy for High-Risk Endometrial Cancer Patients After Surgery

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Docetaxel
  • Sponsor:Merck Sharp & Dohme LLC

Neoplasm

Not recruiting

Study of Olaparib and Pembrolizumab for Patients with Advanced Cancer with HRRm or HRD Mutations

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Safety and Effects of BIIB080 for Patients Aged 50-80 with Mild Cognitive Impairment or Mild Alzheimer's Disease Dementia

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:BIIB080
  • Sponsor:Biogen Idec Research Limited

Study of RO7247669 and Nab-Paclitaxel vs. Pembrolizumab and Nab-Paclitaxel for Patients with Untreated, PD-L1 Positive, Advanced Triple-Negative Breast Cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Study of IO102-IO103 and Pembrolizumab for Patients with Resectable Melanoma and Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:IO103 acetate
  • Sponsor:Io Biotech ApS

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden

Clinical research in Höllviken

What the registry says about research in the country

01 Respiratory Medicine

Innovative research focusing on Chronic Obstructive Pulmonary Disease (COPD) management through advanced combination therapy approaches. The studies aim to evaluate triple therapy effectiveness compared to dual bronchodilator treatments for improving cardiopulmonary outcomes.

  • Respiratory Disease Management
  • Cardiopulmonary Health
  • Therapeutic Combinations

These trials explore enhanced treatment options for patients with chronic respiratory conditions, focusing on improving their quality of life through optimized medication combinations.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.